A Trial-Based Cost-Effectiveness Analysis of Erlotinib Alone versus Platinum-Based Doublet Chemotherapy as First-Line Therapy for Eastern Asian Nonsquamous Non–Small-Cell Lung Cancer

INTRODUCTION: Lung cancer, the most prevalent malignant cancer in the world, remains a serious threat to public health. Recently, a large number of studies have shown that an epidermoid growth factor receptor-tyrosine kinase inhibitor (EGFR TKI), Erlotinib, has significantly better efficacy and is b...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Siying, Peng, Liubao, Li, Jianhe, Zeng, Xiaohui, Ouyang, Lihui, Tan, Chongqing, Lu, Qiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3592875/
https://www.ncbi.nlm.nih.gov/pubmed/23520448
http://dx.doi.org/10.1371/journal.pone.0055917

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3592875/
https://www.ncbi.nlm.nih.gov/pubmed/23520448
http://dx.doi.org/10.1371/journal.pone.0055917

Ejemplares similares